Recent Fluvoxamine COVID benefits discovered using Cytel-designed platform trial

The recently announced benefits of fluvoxamine, an inexpensive drug currently approved as an antidepressant, for treating COVID-19, were confirmed thanks to a platform research study, the TOGETHER Trial, which included key design and implementation contributions from Cytel researchers. According to research study data, Fluvoxamine was found to reduce the number of COVID-19 patients ending up in hospital by approximately 30 percent.

Read the source article at Financial Buzz
2021-09-13 07:00:00